Kathleen Gray

788 total citations · 1 hit paper
33 papers, 539 citations indexed

About

Kathleen Gray is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Kathleen Gray has authored 33 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Kathleen Gray's work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (7 papers) and Viral-associated cancers and disorders (6 papers). Kathleen Gray is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (7 papers) and Viral-associated cancers and disorders (6 papers). Kathleen Gray collaborates with scholars based in United States, United Kingdom and Netherlands. Kathleen Gray's co-authors include Samuel H. Speck, John R. Anderson, R. B. Goudie, G. P. Sandilands, John R. Anderson, J. McQuillin, Donald E. Macfarlane, R. G. Sommerville, J. Craig Forrest and Janice M. Moser and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Kathleen Gray

30 papers receiving 484 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Kathleen Gray

Since Specialization

Citations

This map shows the geographic impact of Kathleen Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Gray more than expected).

Fields of papers citing papers by Kathleen Gray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Gray. The network helps show where Kathleen Gray may publish in the future.

Co-authorship network of co-authors of Kathleen Gray

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Gray. A scholar is included among the top collaborators of Kathleen Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Gray. Kathleen Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab: Highlights From Pharmacists’ Perspectives 2025 ·Journal of the Advanced Practitioner in Oncology ·(unknown), (unknown), (unknown), R. Donald Harvey, (unknown), Kathleen Gray, Thomas Renaud, Jaszianne Tolbert, Scott A. Soefje	0
2	Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study. 2025 ·Journal of Clinical Oncology ·Rakesh Popat, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, Richard L. Doty, (unknown), Brea Lipe, Leo Rasche, Ajai Chari, (unknown), Shaozhou K. Tian, Deeksha Vishwamitra, (unknown), Jennifer Schultz, (unknown), Kathleen Gray, (unknown), Mariana F. Fernández, Keqin Qi, Larysa Sanchez	0
3	P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Eric M. Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Xinke Zhang, Luciano da Fontoura Costa	1
4	P-077 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Carolina Schinke, Ravi Vij, Sundar Jagannath, Larysa Sanchez, Matthew J. Pianko, Andrzej Jakubowiak, Tara Masterson, Michela Campagna, (unknown), Kathleen Gray, Thomas Renaud, Bonnie Lau, Gareth J. Morgan	2
5	P-066 Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Rakesh Popat, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, Richard L. Doty, (unknown), Brea Lipe, Leo Rasche, Ajai Chari, (unknown), (unknown), Deeksha Vishwamitra, (unknown), (unknown), (unknown), (unknown), (unknown), Kathleen Gray, (unknown), Larysa Sanchez	1
6	GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review breakdown → 2024 ·Blood Cancer Journal ·Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar J. Bahlis, Ajai Chari	51
7	Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma 2024 ·Seminars in Oncology Nursing ·(unknown), (unknown), (unknown), (unknown), (unknown), Stephanie Rogers, (unknown), Lisa O’Rourke, Kathleen Gray, Jaszianne Tolbert, Thomas Renaud, Saurabh Patel, (unknown), (unknown)	3
8	Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari, Amrita Krishnan, Leo Rasche, Jing Christine Ye, Alfred L. Garfall, Rakesh Popat, Brea Lipe, Xiang Qin, Michela Campagna, Tara Masterson, (unknown), Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, (unknown), Kathleen Gray, Colleen Kane, Christoph Heuck, Niels W.C.J. van de Donk	19
9	Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Eric M. Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, (unknown), Luciano J. Costa	0
10	Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review 2024 ·Blood Cancer Journal ·Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar J. Bahlis, Ajai Chari	2
11	Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers 2023 ·JCO Oncology Practice ·Scott A. Soefje, (unknown), (unknown), Samir Awasthi, Thomas S. Lin, Shuchita Kaila, (unknown), (unknown), (unknown), (unknown), Kathleen Gray, Shaji Kumar	7
12	Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Shebli Atrash, Philippe Thompson‐Leduc, Ming‐Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie‐Hélène Lafeuille, David Jayabalan, Patrick Lefèbvre, Adriana Rossi	1
13	Patient Characteristics, Treatment Patterns and Outcomes Among Black and White Patients with Multiple Myeloma Initiating Daratumumab: A Real-World Chart Review Study 2021 ·Blood ·Shebli Atrash, Philippe Thompson‐Leduc, Ming‐Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie‐Hélène Lafeuille, Patrick Lefèbvre, Adriana Rossi	1
14	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study 2021 ·BMC Cancer ·Shebli Atrash, Philippe Thompson‐Leduc, Ming‐Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie‐Hélène Lafeuille, Patrick Lefèbvre, Adriana Rossi	18
15	Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma 2020 ·Blood ·Eric M. Ammann, Annette Lam, Wenze Tang, Tobias Kampfenkel, Mohit Sharma, (unknown), Shuchita Kaila, Alex Z. Fu, Kathleen Gray, Jianming He	1
16	Characterization of Omental Immune Aggregates during Establishment of a Latent Gammaherpesvirus Infection 2012 ·PLoS ONE ·Kathleen Gray, Christopher M. Collins, Samuel H. Speck	14
17	Ex Vivo Stimulation of B Cells Latently Infected with Gammaherpesvirus 68 Triggers Reactivation from Latency 2005 ·Journal of Virology ·Janice M. Moser, Jason W. Upton, Kathleen Gray, Samuel H. Speck	31
18	Characterization of hepatic growth hormone binding in domestic poultry 1991 ·General and Comparative Endocrinology ·Kathleen Gray, R. Vasilatos-Younken, (unknown), K.E. Nestor	2
19	Ontogeny of growth hormone (GH) binding in the domestic turkey: evidence of sexual dimorphism and developmental changes in relationship to plasma GH 1990 ·Journal of Endocrinology ·R. Vasilatos-Younken, Kathleen Gray, (unknown), K.E. Nestor, (unknown), James L. Rosenberger	16
20	Human Lymphocyte Sub-Populations and K Cells 1976 ·International Archives of Allergy and Immunology ·G. P. Sandilands, Kathleen Gray, (unknown), Karin S. Froebel, John R. Anderson	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact